Therapeutic efficacy of extracellular vesicles to suppress allograft rejection in preclinical kidney transplantation models: A systematic review and meta-analysis

Yitian Fang; Sarah Bouari; Martin J Hoogduijn; Jan N M Ijzermans; Ron W F de Bruin; Robert C Minnee

doi:10.1016/j.trre.2022.100714

Therapeutic efficacy of extracellular vesicles to suppress allograft rejection in preclinical kidney transplantation models: A systematic review and meta-analysis

Yitian Fang, Sarah Bouari, Martin J Hoogduijn, Jan N M Ijzermans, Ron W F de Bruin, Robert C Minnee^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › Academic › peer-review

6 Citations (Scopus)

121 Downloads (Pure)

Abstract

BACKGROUND:

Kidney transplantation is the optimal treatment of end-stage renal disease. Extracellular vesicles (EVs) have tremendous therapeutic potential, but their role in modulating immune responses in kidney transplantation remains unclear.

METHODS:

We performed a systematic review and meta-analysis to investigate the therapeutic efficacy of EVs in preclinical kidney transplant models. Outcomes for meta-analysis were graft survival and renal function. Subgroup analysis was conducted between immune cell derived EVs (immune cell-EVs) and mesenchymal stromal cell derived EVs (MSC-EVs).

RESULTS:

Seven studies published from 2013 to 2021 were included. The overall effects showed that EVs had a positive role in prolonging allograft survival (standardized mean difference (SMD) = 2.00; 95% confidence interval (CI), 0.79 to 3.21; P < 0.01; I2 = 94%), reducing serum creatinine (SCr) (SMD = -2.19; 95%CI, -3.35 to -1.04; P < 0.01; I2 = 93%) and blood urea nitrogen (BUN) concentrations (SMD = -1.69; 95%CI, -2.98 to -0.40; P = 0.01; I2 = 94%). Subgroup analyses indicated that only immune cell-EVs significantly prolonged graft survival and improve renal function but not MSC-EVs.

CONCLUSIONS:

EVs are promising candidates to suppress allograft rejection and improve kidney transplant outcome. Immune cell-EVs showed their superiority over MSC-EVs in prolonging graft survival and improving renal function. For interpretation of the outcomes, additional studies are needed to validate these findings.

Original language	English
Article number	100714
Journal	Transplantation Reviews
Volume	36
Issue number	4
Early online date	13 Jul 2022
DOIs	https://doi.org/10.1016/j.trre.2022.100714 https://doi.org/10.1016/j.trre.2022.100714
Publication status	Published - Dec 2022

Bibliographical note

Access to Document

1-s2.0-S0955470X22000374-mainFinal published version, 1.36 MBLicence: CC BY-NC-ND

Cite this

Fang, Y., Bouari, S., Hoogduijn, M. J., Ijzermans, J. N. M., de Bruin, R. W. F., & Minnee, R. C. (2022). Therapeutic efficacy of extracellular vesicles to suppress allograft rejection in preclinical kidney transplantation models: A systematic review and meta-analysis. Transplantation Reviews, 36(4), Article 100714. https://doi.org/10.1016/j.trre.2022.100714, https://doi.org/10.1016/j.trre.2022.100714

@article{bf747937edc447588a32a39182b207cb,

title = "Therapeutic efficacy of extracellular vesicles to suppress allograft rejection in preclinical kidney transplantation models: A systematic review and meta-analysis",

abstract = "BACKGROUND: Kidney transplantation is the optimal treatment of end-stage renal disease. Extracellular vesicles (EVs) have tremendous therapeutic potential, but their role in modulating immune responses in kidney transplantation remains unclear.METHODS: We performed a systematic review and meta-analysis to investigate the therapeutic efficacy of EVs in preclinical kidney transplant models. Outcomes for meta-analysis were graft survival and renal function. Subgroup analysis was conducted between immune cell derived EVs (immune cell-EVs) and mesenchymal stromal cell derived EVs (MSC-EVs).RESULTS: Seven studies published from 2013 to 2021 were included. The overall effects showed that EVs had a positive role in prolonging allograft survival (standardized mean difference (SMD) = 2.00; 95% confidence interval (CI), 0.79 to 3.21; P < 0.01; I2 = 94%), reducing serum creatinine (SCr) (SMD = -2.19; 95%CI, -3.35 to -1.04; P < 0.01; I2 = 93%) and blood urea nitrogen (BUN) concentrations (SMD = -1.69; 95%CI, -2.98 to -0.40; P = 0.01; I2 = 94%). Subgroup analyses indicated that only immune cell-EVs significantly prolonged graft survival and improve renal function but not MSC-EVs.CONCLUSIONS: EVs are promising candidates to suppress allograft rejection and improve kidney transplant outcome. Immune cell-EVs showed their superiority over MSC-EVs in prolonging graft survival and improving renal function. For interpretation of the outcomes, additional studies are needed to validate these findings.",

author = "Yitian Fang and Sarah Bouari and Hoogduijn, {Martin J} and Ijzermans, {Jan N M} and {de Bruin}, {Ron W F} and Minnee, {Robert C}",

year = "2022",

month = dec,

doi = "10.1016/j.trre.2022.100714",

language = "English",

volume = "36",

journal = "Transplantation Reviews",

issn = "0955-470X",

publisher = "Elsevier Inc.",

number = "4",

}

Fang, Y , Bouari, S , Hoogduijn, MJ , Ijzermans, JNM , de Bruin, RWF & Minnee, RC 2022, 'Therapeutic efficacy of extracellular vesicles to suppress allograft rejection in preclinical kidney transplantation models: A systematic review and meta-analysis', Transplantation Reviews, vol. 36, no. 4, 100714. https://doi.org/10.1016/j.trre.2022.100714, https://doi.org/10.1016/j.trre.2022.100714

Therapeutic efficacy of extracellular vesicles to suppress allograft rejection in preclinical kidney transplantation models: A systematic review and meta-analysis. / Fang, Yitian ; Bouari, Sarah ; Hoogduijn, Martin J et al.
In: Transplantation Reviews, Vol. 36, No. 4, 100714, 12.2022.

Research output: Contribution to journal › Review article › Academic › peer-review

TY - JOUR

T1 - Therapeutic efficacy of extracellular vesicles to suppress allograft rejection in preclinical kidney transplantation models

T2 - A systematic review and meta-analysis

AU - Fang, Yitian

AU - Bouari, Sarah

AU - Hoogduijn, Martin J

AU - Ijzermans, Jan N M

AU - de Bruin, Ron W F

AU - Minnee, Robert C

PY - 2022/12

Y1 - 2022/12

N2 - BACKGROUND: Kidney transplantation is the optimal treatment of end-stage renal disease. Extracellular vesicles (EVs) have tremendous therapeutic potential, but their role in modulating immune responses in kidney transplantation remains unclear.METHODS: We performed a systematic review and meta-analysis to investigate the therapeutic efficacy of EVs in preclinical kidney transplant models. Outcomes for meta-analysis were graft survival and renal function. Subgroup analysis was conducted between immune cell derived EVs (immune cell-EVs) and mesenchymal stromal cell derived EVs (MSC-EVs).RESULTS: Seven studies published from 2013 to 2021 were included. The overall effects showed that EVs had a positive role in prolonging allograft survival (standardized mean difference (SMD) = 2.00; 95% confidence interval (CI), 0.79 to 3.21; P < 0.01; I2 = 94%), reducing serum creatinine (SCr) (SMD = -2.19; 95%CI, -3.35 to -1.04; P < 0.01; I2 = 93%) and blood urea nitrogen (BUN) concentrations (SMD = -1.69; 95%CI, -2.98 to -0.40; P = 0.01; I2 = 94%). Subgroup analyses indicated that only immune cell-EVs significantly prolonged graft survival and improve renal function but not MSC-EVs.CONCLUSIONS: EVs are promising candidates to suppress allograft rejection and improve kidney transplant outcome. Immune cell-EVs showed their superiority over MSC-EVs in prolonging graft survival and improving renal function. For interpretation of the outcomes, additional studies are needed to validate these findings.

AB - BACKGROUND: Kidney transplantation is the optimal treatment of end-stage renal disease. Extracellular vesicles (EVs) have tremendous therapeutic potential, but their role in modulating immune responses in kidney transplantation remains unclear.METHODS: We performed a systematic review and meta-analysis to investigate the therapeutic efficacy of EVs in preclinical kidney transplant models. Outcomes for meta-analysis were graft survival and renal function. Subgroup analysis was conducted between immune cell derived EVs (immune cell-EVs) and mesenchymal stromal cell derived EVs (MSC-EVs).RESULTS: Seven studies published from 2013 to 2021 were included. The overall effects showed that EVs had a positive role in prolonging allograft survival (standardized mean difference (SMD) = 2.00; 95% confidence interval (CI), 0.79 to 3.21; P < 0.01; I2 = 94%), reducing serum creatinine (SCr) (SMD = -2.19; 95%CI, -3.35 to -1.04; P < 0.01; I2 = 93%) and blood urea nitrogen (BUN) concentrations (SMD = -1.69; 95%CI, -2.98 to -0.40; P = 0.01; I2 = 94%). Subgroup analyses indicated that only immune cell-EVs significantly prolonged graft survival and improve renal function but not MSC-EVs.CONCLUSIONS: EVs are promising candidates to suppress allograft rejection and improve kidney transplant outcome. Immune cell-EVs showed their superiority over MSC-EVs in prolonging graft survival and improving renal function. For interpretation of the outcomes, additional studies are needed to validate these findings.

UR - http://www.scopus.com/inward/record.url?scp=85134185693&partnerID=8YFLogxK

U2 - 10.1016/j.trre.2022.100714

DO - 10.1016/j.trre.2022.100714

M3 - Review article

C2 - 35853384

AN - SCOPUS:85134185693

SN - 0955-470X

VL - 36

JO - Transplantation Reviews

JF - Transplantation Reviews

IS - 4

M1 - 100714

ER -

Therapeutic efficacy of extracellular vesicles to suppress allograft rejection in preclinical kidney transplantation models: A systematic review and meta-analysis

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this